Citius Oncology (CTOR) Finished Goods (2024 - 2026)

Citius Oncology (CTOR) has 3 years of Finished Goods data on file, last reported at $15.7 million in Q1 2026.

• On a quarterly basis, Finished Goods changed N/A year-over-year to $15.7 million in Q1 2026; TTM through Mar 2026 was $15.7 million, a N/A change from a year earlier, with the FY2025 full-year figure at $10.6 million, up 72.42% from the prior year.
• Finished Goods for Q1 2026 stood at $15.7 million, roughly flat from $15.7 million in the prior quarter.
• Over the last five years, Finished Goods for CTOR reached as high as $15.7 million in Q1 2026 and fell as low as $6.1 million in Q3 2024.
• Historically, Finished Goods has averaged $12.0 million across 3 years, with a median of $13.1 million in 2025.
• On a YoY basis, Finished Goods climbed as much as 72.42% in 2025 and fell as far as 72.42% in 2025.
• Year by year, Finished Goods stood at $6.1 million in 2024, then soared by 155.71% to $15.7 million in 2025, then advanced by 0.13% to $15.7 million in 2026.
• Per Business Quant data, the three most recent Finished Goods figures were $15.7 million in Q1 2026, $15.7 million in Q4 2025, and $10.6 million in Q3 2025.